FOLFIRINOX

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OXALIPLATIN` `DRUG-IRINOTECAN` `DRUG-LEUCOVORIN` `DRUG-5-FLUOROURACIL`

ID	`REG-FOLFIRINOX`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-PANCREATIC-2024` `SRC-NCCN-PANCREATIC-2025`

Notes

ACCORD-11: FOLFIRINOX vs gemcitabine in metastatic PDAC, ECOG 0-1 — mOS 11.1 vs 6.8 mo (significant). PRODIGE-24: mFOLFIRINOX adjuvant for resected stage I-III (R0/R1) — mOS 54 mo vs 35 gem-mono. Eligible patients PS 0-1, bilirubin <1.5 ULN, no severe cardiac comorbidity.

Used By

Indication

IND-PDAC-BORDERLINE-RESECTABLE-NEOADJ-FOLFIRINOX - IND-PDAC-BORDERLINE-RESECTABLE-NEOADJ-FOLFIRINOX
IND-PDAC-LAPC-CHEMORADIATION - IND-PDAC-LAPC-CHEMORADIATION
IND-PDAC-METASTATIC-1L-FOLFIRINOX - IND-PDAC-METASTATIC-1L-FOLFIRINOX
IND-RECTAL-TNT-LONG-COURSE-PRODIGE23 - IND-RECTAL-TNT-LONG-COURSE-PRODIGE23

Regimen

REG-MFOLFIRINOX - mFOLFIRINOX (modified FOLFIRINOX, PRODIGE-24 protocol)
REG-NALIRIFOX - NALIRIFOX